Dieter E. Kaufmann | Medicinal Chemistry | Best Researcher Award

Published on by Academic Awards

Prof. Dr. Dieter E. Kaufmann | Medicinal Chemistry | Best Researcher Award

Technical University of Clausthal | Germany

Prof. Dr. Dieter E. Kaufmann is a distinguished organic chemist whose research bridges fundamental synthetic chemistry and applied materials science. His work focuses on the design and synthesis of heterocyclic compounds, polyhalogenated nitrobutadienes, and functionalized benzoates with applications in medicinal chemistry, sustainable materials, and energy systems. He has contributed extensively to the chemical modification of renewable resources, including wood, for enhanced durability, hydrophobicity, and flame retardancy, as well as to the development of organic redox flow batteries. With over 128 publications, 3,676 citations, and an h-index of 30, his research demonstrates high scientific impact, innovation, and interdisciplinary collaboration across organic synthesis, catalysis, and green chemistry.

Profile: Scopus | Orcid 

Featured Publications

  • Kaufmann, D. E., et al. (2025). Synthesis and microbiological activities of 3-nitropyrazolo-[1,5-d][1,2,4]triazin-7(6H)-ones and derivatives. Molecules, 2025.

  • Kaufmann, D. E., et al. (2025). Synthesis, characterization and application of thioindigosulfonic acids as electrolytes in an aqueous organic redox flow battery. ChemElectroChem, 2025.

  • Kaufmann, D. E., et al. (2023). A new way to 2,3,4-trisubstituted benzo[h]quinolines: Synthesis, consecutive reactions and cellular activities. Molecules, 2023.

  • Kaufmann, D. E., et al. (2023). Chemistry of polyhalogenated nitrobutadienes, 19: Synthesis of new types of compounds modulating the biological activity of Type I interferons (IFN-I). Arkivoc, 2023.

  • Kaufmann, D. E., et al. (2022). Intramolecular phosphine-promoted Knoevenagel based redox-reaction. Molecules, 2022.

  • Kaufmann, D. E., et al. (2022). Chemistry of polyhalogenated nitrobutadienes, 17: Efficient synthesis of persubstituted chloroquinolinyl-1H-pyrazoles and evaluation of their antimalarial, anti-SARS-CoV-2, antibacterial, and cytotoxic activities. Beilstein Journal of Organic Chemistry, 2022.

  • Kaufmann, D. E., et al. (2021). Surface tuning of wood via covalent modification of its lignocellulosic biopolymers with substituted benzoates: A study on reactivity, efficiency, and durability. ACS Omega, 2021.

  • Kaufmann, D. E., et al. (2021). Durable modification of wood by benzoylation—Proof of covalent bonding by solution state NMR and DOSY NMR quick-test. Polymers, 2021.

  • Kaufmann, D. E., et al. (2021). Chemical improvement of surfaces. Part 6: Enhanced flame retardancy of Scots pine sapwood by covalent modification with phosphorus and boron functionalized benzoates. Holzforschung, 2021.

  • Kaufmann, D. E., et al. (2021). Surface tuning of wood through chemical modification for enhanced performance and stability. Holzforschung, 2021.

Jing Nie | Medicinal Chemistry | Best Researcher Award

Published on by Academic Awards

Ms. Jing Nie | Medicinal Chemistry | Best Researcher Award

Ms. Jing Nie | Shandong Second Provincial General Hospital | China

Ms. Jing Nie serves as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital and holds the position of Associate Chief Pharmacist. She actively contributes to the advancement of pharmaceutical sciences through her leadership roles in various professional committees, including the Shandong Provincial Hospital Association’s Digital and Intelligent Pharmacy Committee, the Pediatric Rational Drug Use Committee of the Shandong Pharmacists Association, and the Otolaryngology Pharmacy Committee of the Shandong Pharmaceutical Society. She is also a core member of the Rheumatology Committee of the Jinan Association of Integrated Traditional Chinese and Western Medicine, the Antitumor Drug Committee of the Shandong Pharmaceutical Society, the Tumor Pharmacy Branch of the Shandong Anti-Cancer Association, and the Internet Plus Pharmacy Services Committee. Her research focuses on hospital pharmacy, artificial intelligence, pharmacoeconomics, and antitumor drug development. She has published extensively, secured patents, developed software, and led multiple provincial and collaborative projects while contributing to numerous national-level studies.

Publication Profile

Scopus

Education

Ms. Jing Nie earned her doctoral degree in pharmacy, equipping her with a strong academic foundation to contribute to both scientific research and clinical pharmacy practice. Her education combined rigorous theoretical learning with extensive research experience, allowing her to specialize in the integration of hospital pharmacy with advanced technologies such as artificial intelligence and pharmacoeconomics. During her doctoral training, she focused on evidence-based approaches to optimize drug therapy and explored the mechanisms and applications of antitumor drugs. Her academic journey not only strengthened her technical expertise but also instilled in her a deep commitment to innovation, patient safety, and rational drug use. She has built upon her formal education through continuous professional development, actively engaging with academic societies, conferences, and specialized committees that broaden her knowledge and keep her at the forefront of evolving pharmaceutical sciences. Her educational background remains the cornerstone of her contributions to research and practice.

Experience

Ms. Jing Nie has extensive professional experience as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital, where she also serves as Associate Chief Pharmacist. Her experience includes leadership and active participation in multiple prestigious committees, such as those dedicated to digital pharmacy, rational pediatric drug use, otolaryngology pharmacy, rheumatology, and oncology. She has played a key role in advancing pharmaceutical sciences by bridging hospital pharmacy with innovative fields like artificial intelligence and pharmacoeconomics. Her experience is further reflected in her strong publication record, where she has authored and co-authored more than twenty scientific papers, many in high-impact journals. She has successfully applied her expertise to provincial-level projects, cross-disciplinary collaborations, and has contributed significantly to national-level studies. In addition, her practical work includes obtaining multiple patents and software copyrights, reinforcing her ability to translate scientific innovation into practical applications that benefit patients and the healthcare system.

Research Focus

Ms. Jing Nie’s research focus lies at the intersection of pharmaceutical sciences, oncology, and innovative therapeutic strategies. Her work on the advances of HDAC dual inhibitors in breast cancer treatment highlights her commitment to exploring novel drug mechanisms and targeted therapies in oncology. By investigating epigenetic regulation through HDAC inhibition, she contributes to the development of more effective treatments for breast cancer patients, bridging basic research with clinical applications. Beyond oncology, her broader focus includes hospital pharmacy, pharmacoeconomics, artificial intelligence in drug management, and rational drug use. This multidisciplinary approach allows her to integrate clinical practice with cutting-edge research, addressing both the economic and therapeutic aspects of patient care. Her emphasis on anti-tumor drug development, combined with her role in scientific committees and leadership positions, reflects a holistic vision of improving healthcare outcomes through innovation, collaboration, and translational research. Ms. Nie’s focus is well aligned with advancing precision medicine and modern pharmacy.

Publication Top Notes

Advances of HDAC dual inhibitors in breast cancer treatment

Conclusion

Ms. Jing Nie is highly suitable for the Research for Best Researcher Award, given her impactful contributions to pharmaceutical sciences, leadership roles, and innovation in anti-tumor drug research and artificial intelligence. With strategic international engagement and clinical translation of her work, she has the potential to become a globally recognized leader in hospital pharmacy research.

SooHo Yeo | Medicinal Chemistry | Best Researcher Award

Published on by Academic Awards

Dr. SooHo Yeo | Medicinal Chemistry | Best Researcher Award

Research Professor from Yonsei University College of Pharmacy | South Korea

Dr. SooHo Yeo is a distinguished pharmaceutical researcher specializing in pharmaceutics, nanomedicine, and photodynamic cancer therapy. He earned his M.S./Ph.D. from the College of Pharmacy at Chung-Ang University, Seoul, Korea, with a dissertation focused on artificial skin formulation for the topical delivery of adenosine. Currently serving as a Research Professor at Yonsei University, he previously held a similar position at INJE University’s Department of Nanoscience and Engineering. Dr. Yeo’s expertise spans nano/micro-particle drug delivery, solid lipid nanoparticles, liposomes, and cosmetic dermatology. His work includes in vitro toxicology, pharmacokinetic/pharmacodynamic analysis, and OECD-guideline-based skin testing. He has published extensively in top-tier journals such as ACS Omega, Scientific Reports, International Journal of Pharmaceutics, and Pharmaceutics, with research focused on enhancing anticancer efficacy through innovative nanoparticle systems. Dr. Yeo is widely recognized for his interdisciplinary contributions that merge pharmaceutical sciences, biomedical engineering, and clinical research.

Publication Profile

Orcid

Academic Background

Dr. SooHo Yeo earned his M.S./Ph.D. degree from the prestigious College of Pharmacy at Chung-Ang University, located in Seoul, Korea. His academic journey reflects a strong foundation in pharmaceutical sciences, with a focus on drug delivery systems and dermal formulations. His doctoral research, titled “Artificial Skin Formulation for Topical Delivery of Adenosine,” showcases his early commitment to developing innovative therapeutic approaches using transdermal delivery platforms. The dissertation centered on the design and optimization of artificial skin systems to enhance the bioavailability and therapeutic impact of adenosine, a bioactive compound with potential in cosmetic and pharmaceutical applications. This research not only demonstrated Dr. Yeo’s technical expertise in pharmaceutics and cosmeceutics but also laid the groundwork for his later contributions to nanomedicine and photodynamic therapy. His education at Chung-Ang University provided a solid interdisciplinary foundation that continues to shape his impactful research in pharmaceutical innovation.

Professional Experience

Dr. SooHo Yeo has held prominent research positions that underscore his expertise in pharmaceutical sciences and nanotechnology. he has been serving as a Research Professor at the College of Pharmacy, Yonsei University, Incheon, Korea, where he contributes to cutting-edge research in drug delivery systems, photodynamic therapy, and cosmetic formulation development. Prior to this role, Dr. Yeo worked as a Research Professor in the Department of Nanoscience and Engineering at INJE University in Gimhae, Korea. During his tenure at INJE University, he focused on advanced nanomaterials for biomedical applications, integrating nanoscience with pharmacological innovation. His work at both institutions reflects a consistent dedication to interdisciplinary research, bridging pharmaceutical development with nanotechnology and bioengineering. Dr. Yeo’s professional experience highlights his active role in advancing therapeutic strategies through nanomedicine and solidifies his reputation as a leading figure in pharmaceutical and cosmetic research in South Korea.

Research Focus

Dr. SooHo Yeo’s research is firmly rooted in pharmaceutical sciences, with a specialized focus on nanomedicine, drug delivery systems, and photodynamic therapy for cancer treatment. His work centers on the development of advanced nanoformulations such as solid lipid nanoparticles, nanostructured lipid carriers, and lipid-based vesicles to enhance the therapeutic efficacy of anti-cancer agents like purpurin derivatives, doxorubicin, aspirin, and curcumin. A major theme in his research is topical and transdermal delivery systems using biocompatible polymers like hydroxypropyl methylcellulose for treating skin cancer. He also explores emulsion gels, pH-responsive nanocarriers, and cosmeceutical applications to treat or prevent conditions like postoperative adhesions and dermatological issues. His studies include in vitro and in vivo evaluations, highlighting a strong translational approach. Through consistent contributions to peer-reviewed journals, Dr. Yeo has positioned himself at the forefront of targeted drug delivery, phototherapy, and pharmaceutical nanotechnology aimed at improving patient outcomes in oncology and dermatology.

Publication Top Notes

  • Preparation and evaluation of hydroxypropyl methylcellulose‐based film incorporated with aspirin‐loaded solid lipid nanoparticles to treat skin cancer
    Year: 2025

  • Development of nanostructured lipid carriers loaded with purpurin-18 N propargylimide methyl ester to improve photodynamic therapy
    Year: 2025

  • Application of PLGA nanoparticles to photodynamic cancer therapy by encapsulating Purpurin-18-N-hydroxylimide methyl ester
    Year: 2025

  • A Celecoxib-Loaded Emulsion Gel for Enhanced Drug Delivery and Prevention of Postoperative Adhesion
    Year: 2025

  • Encapsulation of synthesized purpurin-18-N-aminoimide methyl ester in lipid nanovesicles for use as agents in photodynamic cancer therapy
    Year: 2025

Conclusion

Dr. SooHo Yeo is a highly qualified candidate for the Research for Best Researcher Award. His cutting-edge work in nanoparticle-based drug delivery systems, photodynamic therapy, and cosmeceutical formulations, combined with an impressive publication record and solid research positions, positions him as a frontrunner in pharmaceutical sciences. While metrics on citations and translational outcomes could further bolster his candidacy, his depth of expertise, innovation, and interdisciplinary application make him strongly suitable for this award.